anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Objective:To investigate the application value of NB CE-Chirp ASSR in the assessment of hearing threshold in children with hearing impairment. Methods:The hearing test results of 44 children with sensorineural hearing loss(88 ears) diagnosed in Shanghai Children's Hospital from January 2023 to December 2023 were retrospectively studied, including 19 ears in mild hearing loss group, 26 ears in moderate group, 20 ears in severe group and 23 ears in extremely severe group. Correlations between auditory brainstem response(ABR) thresholds, pure tone audiometry(PTA) thresholds and NB CE-Chirp ASSR response thresholds in different hearing loss groups were analyzed. Results:The threshold difference between ABR and NB CE-Chirp ASSR(2 000-4 000 Hz) was between 0.50-4.08 dB in different degrees of hearing loss group. There was a significant correlation between NB CE-Chirp ASSR and ABR response threshold in each group(P<0.001), and the correlation coefficients of mild, severe and extremely severe groups were all greater than 0.8, showing a strong correlation. The average threshold difference between PTA and NB CE-Chirp ASSR in each group was between 1.88-3.91 dB. The correlation coefficients were all greater than 0.8, showing a strong correlation. The difference between PTA and NB CE-Chirp ASSR response threshold at 500, 1 000, 2 000 and 4 000 Hz in each groupwas between 0.25-3.84 dB. With the increase of frequency, the correlation coefficient between PTA and NB CE-Chirp ASSR response threshold showed an upward trend. The frequency with the highest coefficient was 4 000 Hz, and the r values were all greater than 0.9, followed by 2 000 Hz, and the correlation coefficient was relatively low at 500 Hz. In the extremely severe group, each frequency coefficient was greater than 0.7, showing a strong correlation. Conclusion:NB CE-Chirp ASSR has good frequency specificity and can reliably assess hearing thresholds in hearing-impaired children.
Micro implement with micro payload is used for painless and safe percutaneous drug delivery. The micro•head made of maltose or saccharide contains drug and stands on micro-stem installed in orifice of stem holder. Non drug micro-stem supports the payload to adjust insertion depth and reach an interest region under skin and is set to come out from the orifice just after insertion. The payload is completely bullet-like inserted into skin and the drug contained micro•head in the upper micro payload is also delivered into skin completely. The bioavailability 100% is accomplished. The inserted payload solves in internal water and releases drug around the interest region. The implement is composed of payload and holder. The payload is unified of micro•head with drug and non-drug micro•stem. All saccharides means ecologically disposable.
Lung cancer is one of the most common types of cancer and is also the most common cause of death from cancer. NSCLC accounts for 85 percent (%) to 90% of lung cancers. Lazertinib is an oral, highly potent, mutant-selective, and irreversible EGFR-tyrosine kinase inhibitor (TKI) targeting both, the T790M mutation and activating EGFR mutations while sparing wild type EGFR. JNJ-61186372 (also referred to as amivantamab), is a low fucose, fully human immunoglobulin G1(IgG1)-based bispecific antibody. As a third generation EGFR-TKI targeting activating EGFR mutations, lazertinib has a distinct mechanism of action from JNJ-61186372, which targets the extracellular domains of both the EGFR and cMet proteins. The distinct mechanisms of action of lazertinib and JNJ-61186372 suggests potential to improve clinical outcomes through the combination of these two molecules. Phase 1 and 1b lazertinib + amivantamab, and Phase 1b LACP combination cohort are divided into 2 periods: screening and treatment period whereas Phase 1b expansion cohorts are divided into 3 periods: screening, treatment, and post-treatment follow up period. Safety assessment will include adverse events (AEs), serious adverse events (SAEs), physical examinations, Eastern Cooperative Oncology Group (ECOG) criteria for performance status, laboratory tests, vital signs, electrocardiograms, chest x-ray, baseline ophthalmologic examination (Phase 1b Expansion Cohorts), echocardiography or multigated acquisition, and concomitant medication usage. The overall duration of the study will be up to 5 years and 2 months.
This is a phase I, non-blinded, non-randomized, pilot trial for safety and efficacy of deep brain stimulation for medically-refractory, repetitive self-injurious behaviours in children with ASD (i.e. secondary stereotypies). The trial will be conducted in compliance with the protocol, GCP and the applicable regulatory requirement(s).

Patients who meet inclusion and exclusion criteria will be identified and recruited the Neurosurgical Clinic at The Hospital for Sick Children. The study will proceed according to the schedule laid out below, and both patients and treating team will be aware of all treatment parameters at all times. Six (6) subjects will be enrolled in this study and study duration for each patient will be one (1) year. Previous phase I trials of DBS in psychiatric and Alzheimer's Disease populations have utilized 6 subjects per surgical target. Such a number is sufficient to demonstrate initial safety, as well as feasibility and clinical effectiveness.
Methods for administering compounds provide a rapid treatment for sickle cell disease (SCD) to inhibit or reverse red blood cell sickling. The compounds are a group of 5-hydroxymethylfurfural (5-HMF) analogs modified to increase water-solubility. The compounds can be formulated in an aqueous carrier and administered intravenously for immediate uptake into red blood cells (RBCs) within hours, rather than days or weeks. In vitro experiments demonstrated rapid uptake into RBCs and increased O 2  affinity of HbS to an equilibrium point within 30 to 90 minutes. The compounds have a desired level of safety as well as a short half-life, both of which are compatible with acute usage. Thus, the methods of treatment rapidly achieve therapeutic steady-state drug levels, making it possible to deliver a treatment in critical emergency care situations to prevent, reverse and otherwise treat acute sickling or anemia.
Placebo group participants will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, water soluble CoQ10 (Q10Vital®): 0 mg, vitamin C: 0 mg, vitamin A: 0 μg, biotin: 0 μg); continous administration of placebo product for 12 weeks.
PURPOSE:A blood sugar lowering agent having low toxicity and durability of action, obtained by dialyzing a water-soluble component in blue juice of green leaves of wheat or such against water and using an undialyzed fraction soluble in water subjected to dialysis treatment as an active ingredient. CONSTITUTION:A blood sugar lowering agent containing an undialyzed fraction soluble in water subjected to dialysis treatment obtained by dialyzing a water-soluble component in blue juice of green leaves of wheat or such against water as an active ingredient. In order to separate and collect the fraction, blue juice of green leaves of wheat or such, e.g. barley, wheat, rye, etc. is preferably subjected to solid-liquid separating means to remove a solid component, a water- soluble component system is dialyzed against water, water-soluble salts and relatively low-molecular weight components are dialyzed and removed and an undialyzed component solution soluble in water subjected to dialysis treatment is collected as the aimed fraction. Although the fraction has strongly lowering action on blood sugar comparable with that of insulin, it has no side effects as insulin does and has extremely low toxicity and high safety.
Participants in this aNHL arm received an intravenous infusion of obinutuzumab 1600 mg on Days 1 and 8 of Cycle 1 and obinutuzumab 800 mg on Day 1 of Cycles 2-8 for a maximum of 8 cycles and 9 infusions. Each cycle was 21 days.
The investigators will be recruiting 12 to 17-year 11-month old patients with a Class II molar relationship,who are presenting for comprehensive orthodontic treatment at the Postgraduate orthodontic clinic at University at Buffalo School of Dental Medicine. Recruited subjects will be randomized into one of 2 groups. Both groups will be receiving a method of Class II correction using the Sagittal First approach, which means the Class II molar relationship will be corrected prior to the leveling and aligning phase of orthodontic treatment. Subjects will be treated using either the Carriere Motion Appliance (CMA), or a sectional appliance fabricated with materials that are commonly found in orthodontic practice. Both appliances will be used according to the CMA guidelines. After Class II correction and removal of appliance, and prior to the next stage of treatment, an additional digital scan of the mouth and a lateral cephalometric radiograph will be taken. Dental and skeletal measurements from initial cephalometric radiographs and models will be subtracted from the corresponding measurements taken on radiographs and models obtained after Class II correction, and comparisons will be made between the two treatment treatment groups. Efficiency will be determined by number of months until Class II molar and canine correction was obtained, and efficacy will be determined by the skeletal and dental measurements obtained.
Because cytarabine is a bone marrow suppressant, anemia, leukopenia, thrombocytopenia, megaloblastosis and reduced reticulocytes can be expected as a result of administration with Cytarabine Injection. The severity of these reactions are dose and schedule dependent. Cellular changes in the morphology of bone marrow and peripheral smears can be expected. 

Following 5-day constant infusions or acute injections of 50 mg/m2 to 600 mg/m2, white cell depression follows a biphasic course. Regardless of initial count, dosage level, or schedule, there is an initial fall starting the first 24 hours with a nadir at days 7 to 9. This is followed by a brief rise which peaks around the twelfth day. A second and deeper fall reaches nadir at days 15 to 24. Then there is a rapid rise to above baseline in the next 10 days. Platelet depression is noticeable at 5 days with a peak depression occurring between days 12 to 15. Thereupon, a rapid rise to above baseline occurs in the next 10 days.
PROBLEM TO BE SOLVED: To provide an antioxidant for external use which is safe for skin, has good feeling and has antioxidation effects.SOLUTION: The antioxidant for external use includes antioxidant plant extract which is obtained by extracting a mixture of Coptis japonica, Phellodendri cortex, Scutellaria root, and Gardenia fruit with ethanol solution. It is desirable that the antioxidant is extracted from a mixture, in mass part, of 0. 2-3.8 parts of Coptis japonica Makino, 0. 2-3.8 parts of Phellodendri Cortex, 0. 3-7.5 parts of scutellaria and 0, 2-5 parts of gardenia with ethanol solution. It is desirable that the antioxidant is blended with a preparation for external use chosen from cosmetics, bathing agents, and detergents.
A novel composite biological agent based on a porous frame material, comprising porous frame materials and biomolecules. The porous frame materials cover a biological product, wherein the porous frame materials are metal-organic frame material (MOFs), covalent organic frame materials (COFs), and hydrogen-bonding organic frame materials (HOFs), and the biomolecules are any one or a combination of antibodies, enzymes, peptides, vaccines, nucleotides, and virus species. The composite biological agent uses the porous frame materials and biomolecules to form a porous frame material/biomolecule complex, and the biomolecules are coated to achieve the protection effect. Under the premise of remaining biomolecule activity, the system can achieve efficient separation and recovery of the porous materials and the biomolecules, so that the technical problems of synthesis, storage, release, etc. are solved, a good technical effect is achieved, and the biomolecules are effectively protected. The system is applied to the storage and transportation of biological agents and preparation of novel agents.
In order to bring research on cat dander allergy a step further we aim to investigate cat dander allergy symptoms and record them in a natural environment, respectively, i.e. at the participant's home. For this purpose we aim to test a new self-assessed, homebased symptom score (called HypoScore). The participants will perform 8 provocation tests. Every provocation test consists of petting the cat until the participants become symptomatic. The participants have to pet the cat everytime in the same manner. Directly before and after the provocation test the symptoms will be recorded in the eCRF by using an iPad mini.
Treatment as Usual parents will be contacted after 8 weeks to complete follow-up interview. Will not receive PURPOSE intervention.
PROBLEM TO BE SOLVED: To obtain the subject composition having high safety, capable of controlling accumulation of lipid in vivo, consequently contributing to suppression and prevention of obesity by including a plant of the family Labiatae having inhibitory effects on lipase and/or an extracted oil of plant of the family Labiatae and a raw material of product. SOLUTION: This composition contains a plant of the family Labiatae [e.g. rosemary and ENNMEISOU (grass of Plectranthus rugosus)] and an extracted oil of plant of the family Labiatae alone or in a mixture as an active ingredient. The extracted oil of plant of the family Labiatae is preferably an extracted oil extracted with water and/or a polar organic solvent. The plant of the family Labiatae is preferably a plant belonging to the genus Rosmarius or Isodon. The plant of the family Labiatae is preferably rosemary, Isodon japonica, Isodon trichocarpus or Isodon sikokianus var. intermodius.
Participants will be asked to remove all accessories from the forearm, wrist, fingers and to roll up any clothing until at least 5 cm above the humeral condyles are exposed. They will be instructed to perform conventional surgical scrubbing and to dry their hands with a conventional paper towel. The research assistant will open the opaque envelope, which will indicate that the participant needs to dry their hands with one surgical towel.
INTRODUCTION: Our study aims to characterize the results of Monteggia fractures treated in our practice and to determine factors associated with good or poor outcomes.
METHODS: A retrospective review of children aged 17 and under with acute, subacute, or chronic Monteggia fractures who were treated at our institution was performed. The primary outcomes were initial reduction and maintenance of joint reduction, while the secondary outcomes were elbow flexion/extension and forearm supination/pronation.
RESULTS: Seventeen patients with Monteggia fractures were identified. Two patients were excluded: 1 was lost to follow-up and 1 had congenital absence of the elbow flexors. Thus, our final cohort was 15 patients (acute n = 3, subacute n = 4, chronic group n = 8). Median final follow-up was 1.9 years (range = 34 days-8 years).
CONCLUSION: Preoperative range of motion (ROM) was the most important factor in determining postoperative ROM in this cohort of patients with chronic Monteggia fractures. All patients who presented with excellent preoperative ROM, regardless of their timing category, had an excellent ROM outcome. Time from initial injury also played an important role. All patients in the acute and subacute categories had good or excellent postoperative ROM. Patients who were further from the initial injury were more likely to present with worse preoperative ROM and, in turn, had worse outcomes with postoperative ROM.
Amblyopia is the most common cause of monocular visual impairment in both children and young and middle-aged adults. Both patching and atropine are accepted treatment modalities for the management of moderate amblyopia in children.1 Many practitioners prescribe 2 hours daily patching as initial therapy for amblyopia. However, many children fail to achieve normal visual acuity in the amblyopic eye with this regimen. In a randomized trial conducted by PEDIG comparing patching regimens, 71 of 92 patients with moderate amblyopia (77%) had amblyopic eye visual acuity of 20/32 or worse after 4 months of patching 2 hours daily.2 In another PEDIG randomized trial comparing patching to spectacles alone after a period of refractive adaptation, patients were treated with 2 hours daily patching and followed every 5 weeks until there was no improvement in amblyopic eye acuity. Fifty-five of 70 patients with moderate amblyopia (79%) and 14 of 14 patients with severe amblyopia (100%) had best-measured amblyopic eye visual acuity of 20/32 or worse after a median treatment period of 10 weeks.3 When improvement with initial therapy stops and amblyopia is still present, treatment options include increasing the dosage of current treatment, switching to another treatment, maintaining the same treatment and dosage for additional months, or combining treatments. Many clinicians will choose to increase the dosage of the current treatment, in part because families have become comfortable with that particular mode of treatment. However, it is unknown whether increasing occlusion dosage will improve amblyopic eye visual acuity in these patients. We are unaware of any reports of response to intensified treatment of amblyopia.
PURPOSE:To provide a dentine-fortifying agent containing an aluminum compound astringent and a pharmacologically permissible anionic surfactant, and effective to fix the protein of dentine, to improve the resistance to the dissolution of collagen with enzyme, and to give a dentine having improved acid- resistance. CONSTITUTION:The objective dentine-fortifying agent contains (A) 5-30W/V% aluminum compound astringent (e.g. aluminum chloride, sodium aluminum sulfate, etc.) and (B) 0.01-2.0W/V% pharmacologically permissible anionic surfactant (e.g. alkylsulfate salt, polyoxyethylenealkylsulfate salt. etc.). The dentine- fortifying agent is useful for the suppression of the hypersensitivity of exposed dentine caused by the grinding of the enamel and of the progress of secondary caries of dentine and fortifies the dentine without causing the blackening of the tooth and strong stimulation to the dental pulp.
Participants will not receive intervention for the first 2 months. This period will be used for comparison with the intervention group. At the end of the 2-month delay, they will receive TENS (1 hr AM, 1 hr PM/day, 50 Hz, below pain/motor threshold, using an EMS 7500 TENS unit).
Prolonged use of high doses of orally active 17-alpha-alkyl androgens (methyltestosterone) has been associated with serious hepatic adverse effects (peliosis hepatitis, hepatic neoplasms, cholestatic hepatitis, and jaundice). Peliosis hepatitis can be a life-threatening or fatal complication. Long-term therapy with intramuscular testosterone enanthate has produced multiple hepatic adenomas. Natesto is not known to cause these adverse effects. Nonetheless, patients should be instructed to report any signs or symptoms of hepatic dysfunction (e.g., jaundice). If these occur, promptly discontinue Natesto while the cause is evaluated.
The present invention discloses a rifamycin sodium injection and a freeze-dried injection formula and the preparation method. The preparation process is simple and the products greatly improve the stability of rafamycin sodium, stabilize and control the quality. The injection contains  C37H47NO12 proportion of rifamycin sodium, 1.0 to 2.0 proportion of organic solvent for injection, 0.008 to 0.016 proportion of antioxidant, proper amount of pH regulator to regulate the pH value to between 5.0 to 7.5, and the allowance is water for injection. The freeze-dried injection contains C37H47NO12 proportion of rifamycin sodium, 20220 to 0.16 proportion of antioxidant, 0.12 proportion of mannitol, proper amount of regulator to regulate the pH value to between 5.0 to 7.5. Formula dosage of antioxidant is added with water for injection to dissolve, added with organic solvent for injection, added with C37H47NO12 proportion of rifamycin sodium, and the pH value is regulated to between 5.0 to 7.0. And then the formula dosage is added with activated carbon for injection with an amount of 0.1 percent of the solution, and is stirred for 10 minutes, filtered and decarbonized through 0.2 Mu m microporous membrane, replenished with water for injection to total content, bottled in 1 to 20ml brown bottle biocare, aerated with nitrogen and sealed. Then the dosage is sterilized in 100 temperature vapor, cooled, tested and packaged to produce finished product.
PURPOSE:To alleviate an operator's burden by judging if the data of an image should be transferred to an external device or not by predetermining and storing the state of having connection or not to the external device and transferring an image file to the external device preset. CONSTITUTION:A preset arrangement of external devices is stored in an image memory device 25. Electric image signals read with an image reading device are converted with a radioactive image input device 24 into digital image data, read into a controller 8, and stored in a device 25. A file made of digital image data added with additional image information is stored in the device 25. Registration of the stored data to each cue 28 of the external device stored as having connection in the device 25 is performed. The registered image file is transferred to the corresponding external device. In this way, waste of time is eliminated because the state of having or not having the connection to the external device is stored in advance and, transfer of an image file for instance to preset hard copy device 29 and host computer 30 is performed by the registration to the cue 28.
For the production of sterile pharmaceuticals, the pharmaceutical particles (a) are washed in a solvent (b) to remove any dirt and sterilize them by removing the outer particle layers together with impurities and any microbial contamination. For the production of sterile pharmaceuticals, the pharmaceutical particles (a) are washed in a solvent (b) to remove any dirt and sterilize them by removing the outer particle layers together with impurities and any microbial contamination. The detached particle skins are gathered and carried away by the solvent. The undissolved and cleaned particles settle as a sediment (c). The used solvent (d), together with its carried impurities, is passed through a sterile filtration (4,5), and the sediment (c) of cleaned particle matter is combined with the sterile filtrate (e) and then separated into solvent and sterile pharmaceutical material (f). The washing stage moves the particles against gravity or against a centrifugal action.
The first 15 participants with fibroblast activation protein-alpha positive (FAP+) tumors will be treated at the RP2D and dosing schedule as determined in Part 1, and will undergo paired tumor biopsies for biomarker assessments. Up to 5 participants with FAP+ tumors will undergo baseline and on-treatment tumor biopsies for biomarker assessments at a dose below the RP2D. The dose for these participants can be escalated to RP2D after 4 weeks of treatment and upon completion of biomarker assessment.